Quercetin and Zinc: Zelenko Treatment Protocol (July 2021)
Dr. Zelenko’s main hypothesis based on the data showing that early intervention and treatment of high-risk patients with COVID-19 results in significantly few hospitalizations and deaths. This treatment regimen involving zinc, low-dose hydroxychloroquine, and azithromycin is also apparently known as, “The Zelenko Protocol.”
Update: Recently, Ivermectin has come to the fore as a more effective (also long standing, cheap, generic drug), in all three stages of COVID-19. Dr Zelenko has also updated his protocols to incorporate ivermectin as an option for both the prophylactic and treatment protocols as shown below. COVID-19 is a highly dynamic topic. Please refer to the latest FLCCC protocol (June 30, 2021 version).
Quercetin and Zinc
Quercetin is a natural antihistamine and anti-inflammatory plant pigment that boosts your immune system and may work to control viral replication, according to some research. It allows zinc to exert its proven antiviral properties; in treating COVID-19, quercetin may also lower inflammation, help clear mucus, prevent ventilator-induced damage and support immunity.
Foods high in quercetin include onions, kale, tomatoes, broccoli, asparagus, berries, red wine, citrus fruits, cherries, and tea.
According to the research, quercetin has been shown to help fight obesity, Type 2 diabetes, circulatory dysfunction, chronic inflammation and mood disorders. It has even been found to help lower blood pressure. Researchers have found that quercetin can trigger tumor regression and begin the process of apoptosis. This is programmed cell death, without which cells can grow uninterrupted and develop into cancerous growths.
Zelenko Covid-19 Prophylaxis Protocol
Low Risk Patients
Young healthy people do not need prophylaxis against Covid 19. In young and healthy people, this infection causes mild cold-like symptoms. It is advantageous for these patients to be exposed to Covid-19, build up their antibodies and have their immune system clear the virus. This will facilitate the development of herd immunity and help prevent future Covid-19 pandemics. However, if these patients desire prophylaxis against Covid-19, then they should take the protocol noted below.
Moderate Risk Patients
Patients from this category are healthy but have high potential viral-load exposure. This group includes medical personnel, caregivers of high-risk patients, people who use public transportation, first responders and other essential personnel who are crucial to the continued functioning of society. These patients should be encouraged to take prophylaxis against Covid-19 in accordance with the protocol noted below.
High Risk Patients
- Zinc (elemental) 25mg 1 time a day (PubMed) (Amazon)
- Vitamin D3 5000 iu 1 time a day (vdnmeta.com) (Amazon)
- Vitamin C 500 mg twice a day (PubMed) (Amazon)
- Quercetin 500mg 1 time a day (Amazon)
- Ivermectin 0.2 mg/kg — one dose on day 1 and day 3, then take one dose weekly (ivmmeta.com). (Find a Doctor)
- Vitamin D3 5000 IU/day or 50000 IU once a week
- Vitamin C 1000mg once a day
- Quercetin 500mg/day
- Zinc 25-50mg/day
Source: Page 16 of FLCCC Alliance – COVID-19 Management Protocol (version May 25, 2021)
Zelenko Protocol - Treatment Plan for Patients with Covid-19 symptoms
Fundamental Principles (Dr Zelenko Protocol When to Start)
Patient CategoriesLow risk patient - Younger than 45, no co-morbidities, and clinically stable
High risk patient - Older than 45, younger than 45 with co-morbidities, or clinically unstable
Low risk patients - over the counter options:
Supportive care with fluids, fever control, and rest
- Elemental Zinc 50-100mg once a day for 7 days
- Vitamin C 1000mg 1 time a day for 7 days
- Vitamin D3 10,000iu once a day for 7 days or 50,000iu once a day for 1-2 days
- Azithromycin 500mg 1 time a day for 5 days OR Doxycycline 100mg 2 times a day for 7 days
- Hydroxychloroquine (HCQ) 200mg 2 times a day for 5-7 days (ScienceDirect)
Ivermectin 0.4-0.5mg/kg/day for 5-7 days (ivmmeta.com). (Find a Doctor)
Either or both HCQ and IVM can be used, and if one only, the second agent may be added after about 2 days of treatment if obvious recovery has not yet been observed etc.
If HCQ is not available, Quercetin 500mg 3 times a day for 7 days OR
EGCG 400mg 2 times a day for 7 days
Other treatment options
- Dexamethasone 6-12mg 1 time a day for 7 days OR Prednisone 20mg twice a day for 7 days, taper as needed
- Budesonide 1mg/2cc solution via nebulizer twice a day for 7 days
- Blood thinners (i.e. Lovenox, Eliquis, Xarelto, Pradaxa, Aspirin) (Amazon)
- Colchicine 0.6mg 2-3 times a day for 5-7 days (MedRxiv 2021)
- Monoclonal antibodies
- Home IV fluids and oxygen
About Dr Vladimir ZelenkoHe graduated with a B.A. degree with high honors in Chemistry from Hofstra University. After receiving an academic scholarship to attend S.U.N.Y. at Buffalo School of Medicine, he earned his M.D. degree in May 2000. Dr. Zelenko completed his family medicine residency at South Nassau Communities Hospital in Oceanside, N.Y. in May 2004. Since then, Dr. Zelenko has practiced family medicine in New York’s Hudson Valley. He has been described by his patients as like a family member to thousands of families, and is a medical adviser to the volunteer ambulance corps in Kiryas Joel, New York.
When asked about studies that seemed to discredit the efficacy of HCQ in treating the Chinese coronavirus, Zelenko explained “You don’t fire a gun without a bullet in it and then say the gun doesn’t work when you don’t kill the target. The studies that were done on HCQ did not include the use of Zinc. HCQ is what opens the cell and enables Zinc to attack the virus. One is not effective without the other, or without a suitable substitute for HCQ. The studies were designed to fail.”
Dr. Zelenko says that both prophylaxis measures and actual case treatments need to be customized to the individual. As a general rule, he says, those people who are in the higher risk groups, both by age and by other pre-existing conditions, require more aggressive actions on both the preventative and diagnostic side.
“This virus remains relatively stable inside the host for about the first five days,” Zelenko says. “After that it starts to multiply rapidly. It also starts to migrate from sinus to lungs and cardio areas where involvement becomes more severe and treatment becomes more difficult. The key is early intervention.” Zelenko again mentioned his 84% success rate in high-risk patients.
Scientific Papers from Dr. Zelenko and his collaborators
- Kory, Pierre MD, Meduri, Gianfranco Umberto MD, Varon, Joseph MD, Iglesias, Jose DO, Marik, Paul E. MD: Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, American Journal of Therapeutics: May Jun 2021 - Volume 28 - Issue 3 - p e299-e318
- R. Derwand, M. Scholz, "Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?", Medical Hypotheses 142 (2020), 109815
- Scholz, M.; Derwand, R.; Zelenko, V. "COVID-19 outpatients - early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study", International Journal of Antimicrobial Agents 56 (2020), 106214 [press release]
- Peter A. McCullough, Ronan J.Kelly, Gaetano Ruocco, Edgar Lerma, James Tumlin, Kevin R.Wheelan, Nevin Katz, Norman E. Lepor, Kris Vijay, Harvey Carter, Bhupinder Singh, Sean P.McCullough, Brijesh K.Bhambi, Alberto Palazzuoli, Gaetano M.De Ferrari, Gregory P.Milligan, TaimurSafder, Kristen M.Tecson, Harvey A.Risch: "Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection", The American Journal of Medicine 134 (2020), 16-22
- Peter A. McCullough, Paul E. Alexander, Robin Armstrong, Cristian Arvinte, Alan F. Bain, Richard P. Bartlett, Robert L. Berkowitz, Andrew C. Berry, Thomas J. Borody, Joseph H. Brewer, Adam M. Brufsky, Teryn Clarke, Roland Derwand, Alieta Eck, John Eck, Richard A. Eisner, George C. Fareed, Angelina Farella, Silvia N. S. Fonseca, Charles E. Geyer, Jr., Russell S. Gonnering, Karladine E. Graves, Kenneth B. V. Gross, Sabine Hazan, Kristin S. Held, H. Thomas Hight, Stella Immanuel, Michael M. Jacobs, Joseph A. Ladapo, Lionel H. Lee, John Littell, Ivette Lozano, Harpal S. Mangat, Ben Marble, John E. McKinnon, Lee D. Merritt, Jane M. Orient, Ramin Oskoui, Donald C. Pompan, Brian C. Procter, Chad Prodromos, Juliana Cepelowicz Rajter, Jean-Jacques Rajter, C. Venkata S. Ram, Salete S. Rios, Harvey A. Risch, Michael J. A. Robb, Molly Rutherford, Martin Scholz, Marilyn M. Singleton, James A. Tumlin, Brian M. Tyson, Richard G. Urso, Kelly Victory, Elizabeth Lee Vliet, Craig M. Wax, Alexandre G. Wolkoff, Vicki Wooll, Vladimir Zelenko."Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)", Reviews in Cardiovascular Medicine 21 (4) (2020), 517-530
- Brian C. Procter, Casey Ross, Vanessa Pickard, Erica Smith, Cortney Hanson, Peter A. McCullough. "Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection", Reviews in Cardiovascular Medicine 21 (4) (2020), 611-614
Ivermectin vs Hydroxychloroquine
Disclaimer: Always see your doctor before taking these supplements and over the counter products. Be aware that most of the dosages are above the recommended dietary allowance (RDA) and therefore such dosages should not be maintained on a long term basis.